Literature DB >> 3009370

Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data.

E P Malaise, B Fertil, N Chavaudra, M Guichard.   

Abstract

The radiosensitivities of human tumor cell lines, grouped into 6 histological categories, have been studied using data from the published literature. The parameters alpha, beta, n, D0, D, and the surviving fraction to 2 Gy (S2) and 8 Gy (S8) were calculated. Only the two parameters mainly derived from the initial part of the survival curve, alpha and D, together with S2, provided data which were correlated with the clinical radioresponsiveness of each histological group. Thus, there are intracellular factors which influence clinical radioresponsiveness whose relative importance varies from one histological cell type to another. The value of D gave the most precise characterization of the average group radiosensitivity. It was possible to compare the in vivo radiosensitivities of non-severely hypoxic cells with those of tumor cells irradiated in vitro for 7 tumor lines grown as xenografts in mice. The average radiosensitivity was 1.9 times less in vivo than in vitro. This difference indicates that, in addition to the intrinsic factors of radioresistance demonstrated in vitro, and independently of severe hypoxia, there are other factors which specifically reduce radiosensitivity in vivo.

Entities:  

Mesh:

Year:  1986        PMID: 3009370     DOI: 10.1016/0360-3016(86)90071-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  Criteria and techniques for analysing cell survival data.

Authors:  D Bettega; P Calzolari; A Ottolenghi; L Tallone Lombardi
Journal:  Radiat Environ Biophys       Date:  1991       Impact factor: 1.925

Review 2.  Less well known parameters of in vitro radiosensitivity.

Authors:  S Vijayakumar; T C Ng; I Koumoundouros; P D Higgins; F J Thomas
Journal:  J Natl Med Assoc       Date:  1989-07       Impact factor: 1.798

Review 3.  Studies of the dose-effect relation.

Authors:  A M Kellerer
Journal:  Experientia       Date:  1989-01-15

4.  Cerenkov Radiation-Induced Photoimmunotherapy with 18F-FDG.

Authors:  Yuko Nakamura; Tadanobu Nagaya; Kazuhide Sato; Shuhei Okuyama; Fusa Ogata; Karen Wong; Stephen Adler; Peter L Choyke; Hisataka Kobayashi
Journal:  J Nucl Med       Date:  2017-04-13       Impact factor: 10.057

5.  Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Authors:  Qi Liu; Meng Wang; Ashley M Kern; Saman Khaled; Jing Han; Beow Y Yeap; Theodore S Hong; Jeff Settleman; Cyril H Benes; Kathryn D Held; Jason A Efstathiou; Henning Willers
Journal:  Mol Cancer Res       Date:  2015-02-09       Impact factor: 5.852

Review 6.  Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer.

Authors:  Aaron T Wild; Yoshiya Yamada
Journal:  Visc Med       Date:  2017-02-03

7.  A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.

Authors:  Robert F Hobbs; Sébastien Baechler; De-Xue Fu; Caroline Esaias; Martin G Pomper; Richard F Ambinder; George Sgouros
Journal:  Med Phys       Date:  2011-06       Impact factor: 4.071

Review 8.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

9.  Proliferation, migration, and invasion of human glioma cells exposed to fractionated radiotherapy in vitro.

Authors:  Jan Gliemroth; Thomas Feyerabend; Christiane Gerlach; Hans Arnold; A Jorge A Terzis
Journal:  Neurosurg Rev       Date:  2003-02-12       Impact factor: 3.042

10.  Radiobiological modeling of interplay between accelerated repopulation and altered fractionation schedules in head and neck cancer.

Authors:  Loredana G Marcu; Eva Bezak
Journal:  J Med Phys       Date:  2009-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.